Hopp til innhold
NHI.no
Annonse

Prognose ved rosen

Innhold i artikkelen

Prognosen er god når man får riktig behandling. Uten behandling kan infeksjonen spre seg til dypere hudlag og bli mer alvorlig. Det er en tendens til at infeksjonen kan oppstå på nytt dersom man har andre tilstander som disponerer for rosen. Omtrent en av fem vil oppleve at tilstanden rammer på nytt.

Annonse

Med adekvat behandling bedres tilstanden som regel i løpet av 24 til 48 timer, og ofte setter legen opp en kontroll. Av og til kan infeksjonen imidlertid bli mer alvorlig.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Erysipelas . Referanselisten for dette dokumentet vises nedenfor

  1. Helsedirektoratet (2021). Nasjonal faglig retningslinje for antibiotika i primærhelsetjenesten nettdokument. Oslo: Helsedirektoratet (sist faglig oppdatert 28. september 2023, lest mai 2025).
  2. Bläckberg A, Trell K, Rasmussen M. Erysipelas, a large retrospective study of aetiology and clinical presentation. BMC Infect Dis. 2015 Sep 30;15:402. PMID: 26424182. PubMed
  3. Hirschmann JV, Raugi GJ. Lower limb cellulitis and its mimics: part I. Lower limb cellulitis. J Am Acad Dermatol 2012; 67: 163. pmid:22794815 PubMed
  4. Norsk barnelegeforening, pediatriveileder: Erysipelas (Rosen). Sist revidert 2022. Nettsiden besøkt 03.06.25 www.helsebiblioteket.no
  5. Goettsch WG, Bouwes Bavinck JN, Herings RM. Burden of illness of bacterial cellulitis and erysipelas of the leg in the Netherlands. J Eur Acad Dermatol Venereol 2006;20:834-839. PubMed
  6. McNamara DR, Tleyjeh IM, Berbari EF. Incidence of lower-extremity cellulitis: a population-based study in Olmsted county, Minnesota. Mayo Clin Proc 2007; 82: 817. pmid:17605961 PubMed
  7. Bruun T, Oppegaard O, Kittang BR, et al. Etiology of Cellulitis and Clinical Prediction of Streptococcal Disease: A Prospective Study. Open Forum Infect Dis. 2015 Nov 25;3(1):ofv181. PMID: 26734653.
  8. Rath E, Skrede S, Mylvaganam H, Bruun T. Aetiology and clinical features of facial cellulitis: a prospective study. Infect Dis (Lond). 2018 Jan;50(1):27-34. Epub 2017 Aug 2. PMID: 28768452. PubMed
  9. Jeng A, Beheshti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine 2010; 89: 217-26. PubMed
  10. Oppegaard O, Mylvaganam H, Kittang BR. Beta-haemolytic group A, C and G streptococcal infections in Western Norway: a 15-year retrospective survey. Clin Microbiol Infect. 2015 Feb;21(2):171-8. Epub 2014 Oct 14. PMID: 25658557. PubMed
  11. Trell K, Rignér S, Wierzbicka M, Nilson B, Rasmussen M. Colonization of β-hemolytic streptococci in patients with erysipelas-a prospective study. Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1901-1906. Epub 2019 Jul 10. PMID: 31292789. PubMed
  12. Eriksson BKG, Karkkonen K, Jorup-Rönström C, Wretlind B. Frequent colonization of betahaemolytic streptococci at various body sites including the perineum and anal canal during erysipelas and cellulitis. Infect Dis (Lond). 2019 Jul;51(7):534-540. Epub 2019 May 15. PMID: 31088328. PubMed
  13. Dupuy A, Benchikhi H, Roujeau J-C, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318: 1591-4. British Medical Journal
  14. Cranendonk DR, Lavrijsen APM, Prins JM, Wiersinga WJ. Cellulitis: current insights into pathophysiology and clinical management. Neth J Med. 2017 Nov;75(9):366-378. PMID: 29219814. PubMed
  15. Stevens DL, Bisno AL, Chambers HF. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59: e10. pmid:24973422 PubMed
  16. Stevens DL, Bryant AE. Streptococcus pyogenes Impetigo, Erysipelas, and Cellulitis. 2022 Sep 7 updated 2022 Oct 4. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations Internet. 2nd ed. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2022 Oct 8. Chapter 23. PMID: 36479753 PubMed
  17. Rath E, Skrede S, Oppegaard O, Bruun T. Non-purulent skin and soft tissue infections: predictive power of a severity score and the appropriateness of treatment in a prospective cohort. Infect Dis (Lond). 2020 May;52(5):361-371. Epub 2020 Feb 13. PMID: 32052670. PubMed
  18. Bruun T, Oppegaard O, Hufthammer KO, et al. Early Response in Cellulitis: A Prospective Study of Dynamics and Predictors. Clin Infect Dis. 2016 Oct 15;63(8):1034-1041. Epub 2016 Jul 11. PMID: 27402819. PubMed
  19. Brindle R.J, O’Neill L.A, Williams OM. Risk, Prevention, Diagnosis, and Management of Cellulitis and Erysipelas. Curr Derm Rep 9, 73–82 (2020). https://doi.org/10.1007/s13671-020-00287-1
  20. Webb E, Neeman T, Bowden F, et al. Compression Therapy to Prevent Recurrent Cellulitis of the Leg. N Engl J Med 2020; 383: 630-639. doi:10.1056/NEJMoa1917197 DOI
  21. Peghin M, Graziano E, Rovelli C, Grossi PA. Prevention and treatment of recurrent cellulitis. Curr Opin Infect Dis. 2023 Apr 1;36(2):95-101. Epub 2023 Feb 9. PMID: 36853755 PubMed
  22. Inghammar M, Rasmussen M, Linder A. Recurrent erysipelas--risk factors and clinical presentation. BMC Infect Dis. 2014 May 18;14:270. PMID: 24884840. PubMed
  23. Oppegaard O, Skrede S, Mylvaganam H, Kittang BR. Emerging Threat of Antimicrobial Resistance in β-Hemolytic Streptococci. Front Microbiol. 2020 May 15;11:797. PMID: 32477287. PubMed
  24. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect 2012;64:148-155. PubMed
  25. Helsedirektoratet. Erysipelas. Nasjonal faglig retningslinje for bruk av antibiotika i sykehus. Sist faglig oppdatert jan. 2018. Siden lest 16.11.2020. www.helsedirektoratet.no
Annonse
Annonse